Iontophoretic transdermal drug delivery: a multi-layered approach by Pontrelli, Giuseppe et al.
Iontophoretic transdermal drug delivery:
a multi-layered approach
Giuseppe Pontrellia, Marco Lauricellaa, Jose´ A. Ferreirab, Gonc¸alo Penab, ∗
bIstituto per le Applicazioni del Calcolo - CNR
Via dei Taurini 19 – 00185 Rome, Italy
aCMUC, Department of Mathematics
University of Coimbra, Portugal
March 6, 2018
Abstract
We present a multi-layer mathematical model to describe the the transdermal drug release
from an iontophoretic system. The Nernst-Planck equation describe the basic convection-
diffusion process, with the electric potential obtained by Laplace equation. These equations
are complemented with suitable interface and boundary conditions in a multi-domain. The
stability of the mathematical problem is discussed in different scenarios and a finite-difference
method is used to solve the coupled system. Numerical experiments are included to illustrate
the drug dynamics under different conditions.
Keywords: drug release, iontophoresis, Nernst-Plank equations, finite-difference methods.
1 Introduction
Traditional transdermal drug delivery (TDD) systems are based on the transport of therapeutic
agents across the skin by passive diffusion. Despite being the subject of intense research over the
past years, it is still unclear the exact mechanism of release and it is often difficult to accurately
predict the drug kinetics [1, 2]. Toxicity can arise if an excessive amount of drug is delivered,
or if it is released too quickly. On the other hand, if the drug is delivered at slow rate, or at
sufficiently low concentrations, the therapeutic effect vanishes [3]. The success of the TDD is
therefore dependent on the amount of drug, rate of release and binding to cell receptors. However,
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the skin has unique structural and physico-chemical properties which differentiate it from other
bio-membranes [4]. The solutes which can be delivered by transdermal route are limited due
to the excellent barrier properties of the stratum corneum, the outermost layer of the epidermis.
As a matter of fact, most drugs delivered by the conventional systems are constituted by small
and highly lipophilic molecules [5]. To increase skin’s drug transport and overcome the barrier
properties of the stratum corneum, innovative technologies have been developed, based on the use
of drug transport enhancers. Two main classes of these have been proposed in the literature. The
first one is composed by chemical penetration enhancers including surfactants, fatty acids, esters
and solvents. These products can have side effects and toxicological implications and appear
to be restricted at the present time to experimental strategies. The second group of enhancers,
the physical ones, apply an external energy to raise the drug delivery into and across the skin or
change the structure of the skin itself and perforate the stratum corneum creating microchannels to
facilitate the drug transport [3, 6].
Drug delivery devices based on the application of an external energy source includes electri-
cally assisted systems where the applied potential generates an additional driving force for the
drug motion (see [7, 8] and references therein). Among such systems, here we are interested in
iontophoretic TDD that several studies indicate as effective in topical and systemic administration
of drugs. It can be used to treat, for instance, dermal analgesia, management of migraine [9], or
acute postoperative pain [10]. More recent applications of iontophoresis have been considered, for
instance, in cancer treatment [11, 12]. In iontophoretic TDD, a charged drug is initially dispersed
in a reservoir (or vehicle) which is in contact with the skin, the target tissue. The electric field
is generated by a potential of low intensity (≈ 1V ) and applied over a limited period of time to
prevent any skin damage. The iontophoretic transport of an active agent across the skin can be
expressed in terms of three independent contributions: passive diffusion due to a chemical gradi-
ent, electromigration due to an electric potential gradient and, with a minor effect, solute kinetics
due to convective solvent flow (electroosmosis)[13, 14]. Moreover, an increased skin permeability
arises from changes in the structure of the skin caused by current flow [15]. It should be remarked
that chemical reactions are also present in TDD, such as drug degradation, binding and unbinding
due to the drug affinity with the polymer chains of the reservoir and/or the target tissue. In this
work we are mainly interested in the physical transport and the other effects are neglected.
Mathematical modelling of iontophoretic process allows to predict drug release from the ve-
hicle and its transport into the target tissue and offers insights into the factors governing drug
delivery, such as the duration of applications and their frequency [16]. For traditional TDD, the
coupling between the diffusion process in the reservoir and in the target tissue has been consid-
ered in [17, 18, 19]. In the majority of TDD models for iontophoretic systems, a constant flux
enters the target tissue – composed of one layer only – and the role of the reservoir of finite ca-
pacity is neglected [6, 13]. In [20], the authors consider a two-compartment diffusion model to
describe the passive drug evolution while a one layer model is used when the electric field is ap-
plied. Tojo has proposed a more general model for iontophoresis incorporating time-dependence,
drug binding and metabolism as well as the convective flow term described above [21]. Pikal de-
veloped a relationship between flux enhancement by treating the process as a simple mass transfer
through aqueous channels [22]. A strategy to combine mathematical modelling with in-vivo and
in-vitro data has been recently proposed in [23]. However, none of the above models considers
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the composite structure of the skin: this aspect has a crucial importance since the drug transport
critically relates to the local diffusive properties and, even more importantly, the potential field
relies on the layer-dependent electrical conductivities. In this paper we overcome this drawback
by considering a coupled diffusion model to describe the drug release from a vehicle in a multi-
layered dermal tissue under the action of an electric field. It is well accepted that the skin has a
inhomogenous structure, being composed of several layers with different thickness and physico-
chemical-electrical properties. The drug transport in this composite medium is described by Fick’s
law for the passive diffusion and by the Nernst-Planck equation for the convective transport in-
duced by the potential gradient. It results a number of coupled convection-diffusion equations
defined in a multi-domain, complemented by suitable conditions on the contact surface and on the
interfaces between the tissue layers.
The paper is organized as follows. In Section 2 we introduce our vehicle-skin multi-layer phys-
ical domain in a general framework. The coupled iontophoretic model is defined in Section 3. The
mathematical problem consists of convection-diffusion equations for the drug concentration cou-
pled with the Laplace equation for the electric potential. Due to the material contrast of the layers,
we end up with a stiff mathematical problem. The complex system is analyzed in Section 4 where
two qualitative results concerning its stability are presented. After a suitable nondimensionaliza-
tion of the initial boundary value problem in Section 5, a finite-difference scheme is described in
Section 6 and finally in section 7 some numerical experiments of TDD are presented and discussed.
2 A multi-layer model for the coupled vehicle-skin system
Let us consider a TDD system constituted by i) a thin layer containing a drug (the vehicle)1 and
ii) the skin where the drug is directed to, separated by a protecting film or a semi-permeable
membrane. This constitutes a coupled system with an imperfect contact interface for the mass flux
between the two media. Because most of the mass dynamics occurs along the direction normal to
the skin surface, we restrict our study to a simplified 1D model. In particular, we consider a line
crossing the vehicle and the skin, pointing inwards, and a Cartesian coordinate x is used along it.
It is well recognized that the skin has a typical composite structure, constituted by a sequence
of contiguous layers of different physical properties and thickness, with drug capillary clearance
(washout) taking place at the end of it (see [4] for an anatomic and physiological description) (figs
1 - 2). The vehicle (of thickness `0) and the skin layers (of thicknesses `1, `1, ..., `n) are treated
as macroscopically homogeneous porous media. Without loss of generality, let us assume that
x0 = 0 is the vehicle-skin interface. In a general 1D framework, let us consider a set of intervals
[xi−1, xi], i = 0, 1, . . . , n, having thickness `i = xi − xi−1, modelling the vehicle (layer 0) and the
skin (layers 1, 2, . . . , n), with L =
∑
i
`i the overall skin thickness (xn = L) (fig. 3).
At the initial time (t = 0), the drug is contained only in the vehicle, distributed with maximum
concentration C and, subsequently, released into the skin. Here, and throughout this paper, a mass
volume-averaged concentration ci(x, t) (mg/cm3) is considered in each layer `i. Since the vehicle
is made impermeable with a backing protection, no mass flux pass through the boundary surface
1This can be the polymeric matrix of a transdermal patch, or a gel film, or an ointment rub on the skin surface, and
acts as the drug reservoir.
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at x = x−1 = −`0. Strictly speaking, in a diffusion dominated problem the concentration van-
ishes asymptotically at infinite distance. However, for computational purposes, the concentration
is damped out (within a given tolerance) over a finite distance at a given time. Such a length,
(sometimes termed as penetration distance), critically depends on the diffusive properties of the
layered medium [24]. At the right end x = L all drug is assumed washed out from capillaries and
a sink condition (cn = 0) is imposed.
3 Transdermal iontophoresis
To promote TDD, an electric field is locally applied in the area where the therapeutic agent has to
be released (iontophoresis): one electrode is placed in contact with the vehicle and the other is in
contact with the target tissue. To simplify we assume that the drug is positively charged, the anode
is at x = x−1 and the cathode is at x = xn (fig. 3). Let Ψ0 and Ψ1, Ψ0 > Ψ1, be the correspondent
applied potential at the endpoints. By mass conservation, the concentration satisfies the following
equation:
∂ci
∂t
+∇ · Ji = 0 (3.1)
and in each layer i the mass flux is defined by the Nernst-Planck flux equation [13]:
Ji = −Di∇ci − uici∇φi, i = 0, 1, . . . , n (3.2)
where φi is the electric potential in layer i and the convective (electroosmotic) term is omitted. Eqn.
(3.2) is the generalized Fick’s first law with an additional driving force which is proportional to
the electric field. The electric mobility is related to the diffusivity coefficient through the Einstein
relation:
ui =
DiziF
RT
, i = 0, 1, . . . , n (3.3)
(cm2 V −1 s−1), where zi ion valence, F the Faraday constant, R the gas constant, T the absolute
temperature. The boundary conditions are
J0 = 0 at x = −`0 = −x−1 (impermeable backing) (3.4)
cn = 0 at x = xn (sink condition due to the capillary washout) (3.5)
The last condition arises because, in deep skin, drug is uptaken by capillary network and is lost
in the systemic circulation: we refer to this as systemically absorbed (shortly “absorbed” ) drug.
At x = 0 we impose the matching of the total fluxes and that they are proportional to the jump of
concentration (Kedem-Katchalski eqn):
J0 = J1 = P (c0 − c1) at x = 0 (3.6)
with P (cm/s) a mass transfer coefficient (includes a drug partitioning and a mass flux resistance).
At the other interfaces we assume a perfect contact and continuity of concentrations and fluxes:
Ji = Ji+1 ci = ci+1 at x = xi, i = 1, 2, . . . , n− 1 (3.7)
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The initial conditions are set as:
c0(x, 0) = C, ci(x, 0) = 0 i = 1, 2, . . . , n (3.8)
3.1 The electric potential field
To solve equations (3.1)–(3.3), in some cases the potential φ is assigned, but in this multi-layer
system we find it as solution of the Poisson equation:
∇ · (σi∇φi) =
∑
k
zkck ' 0 i = 0, 1, . . . , n (3.9)
φ0 = Ψ0 at x = −x−1 (3.10)
φn = Ψ1 at x = xn (3.11)
with σi(cm−1 Ω−1) the electrical conductivities in the layer i [8]. At the interfaces we assume an
electrically perfect contact and we have continuity of potential and fluxes:
−σi∇φi = −σi+1∇φi+1 φi = φi+1 at x = xi i = 0, 1, . . . , n− 1 (3.12)
It is straightforward to verify that the exact solution of the problem (3.9)–(3.12) is
φi(x) = aix+ bi i = 0, 1, . . . , n (3.13)
with the expressions of ai(V/cm) and bi(V ) are computed in the specific cases (see sect. 7).
4 Energy estimates
In this section we establish some energy estimates in the two cases of finite P > 0 (subsection
4.1) and in the limit case P → ∞ (subsection 4.2) at interface condition (3.6), that leads to upper
bound of total drug masses. These results will be used to obtain stability and uniqueness results
under a condition on the applied potential and on the diffusivities. We point out that our analysis
concerns the global energy as well as the total mass of drug in the whole system, and cannot be
carried out in the single layers.
4.1 The general case: imperfect contact
Let (·, ·)i be the usual inner product in L2(xi−1, xi) and ‖·‖i the corresponding norm, i = 0, . . . , n.
From (3.1) we deduce
n∑
i=0
(
∂ci
∂t
, ci
)
i
+
n∑
i=0
(∇ · Ji, ci)i = 0. (4.1)
Combining (4.1) with the boundary conditions (3.4)–(3.5) and the interface conditions (3.6), (3.7)
we get
1
2
ξ′(t) +
n∑
i=0
Di‖∇ci‖2i +
n∑
i=0
(vici,∇ci)i = −P
(
c0(0, t)− c1(0, t)
)2 (4.2)
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where vi = ui∇φi, is the convective velocity induced by the potential field, and ξ(t) =
n∑
i=0
‖ci(t)‖2i
is the total energy. By the Young inequality we have:
(vici,∇ci)i ≥ − 1
42
v2i ‖ci‖2i − 2i ‖∇ci‖2i ,
for any i 6= 0. Then from (4.2) we get
1
2
ξ′(t) +
n∑
i=0
(
Di − 2i
)
‖∇ci‖2i −
n∑
i=0
v2i
2i
‖ci‖2i ≤ −P
(
c0(0, t)− c1(0, t)
)2 (4.3)
Taking 2i = Di in (4.3) we obtain:
ξ′(t)− 2
n∑
i=0
v2i
Di
‖ci‖2i ≤ −2P
(
c0(0, t)− c1(0, t)
)2
. (4.4)
Finally, (4.4) leads to
ξ(t) ≤ eαt
(
ξ(0)− 2P
∫ t
0
e−αs
(
c0(0, s)− c1(0, s)
)2
ds
)
. (4.5)
with α = 2 max
i=0,...,n
v2i
Di
. The upper bound (4.5) shows that the initial boundary value problem (3.1)–
(3.8) is stable for finite t. Through the previous inequality, we prove the uniqueness of the solution
as follows: if we assume that in each sub-interval we have at least two solutions ci and c˜i that
satisfy the same initial condition, then for wi = ci − c˜i we have
ξ(t) ≤ eαt
(
− 2P
∫ t
0
e−αs
(
w0(0, s)− w1(0, s)
)2
ds
)
. (4.6)
This means that ξ(t) ≤ 0 and consequently ci = c˜i, i = 0, . . . , n. The existence of the solution
is guaranteed by showing that an analytic solution can be built as a Fourier series, analogously to
similar diffusion-convective problems in layered systems [18].
The upper bound (4.5) can be used to describe the behavior of the coupled system for the
released mass. Let
Mi(t) =
∫ xi
xi−1
ci(s)ds M(t) =
n∑
i=0
Mi(t) (4.7)
be the mass in the layer i and the total mass, respectively. Being M(t)2 ≤ ξ(t)L , we get, from
equation (4.6), the following upper bound for the drug mass in the coupled system
M(t) ≤
√
Le
α
2
t
(
ξ(0)− 2P
∫ t
0
e−αs
(
c0(0, s)− c1(0, s)
)2
ds
)1/2
. (4.8)
This estimate shows that the larger is P , the smaller is the total mass (i.e. the larger is the
absorbed mass). The above bound depends on the history of concentration jump at contact interface
weighted by controllable quantities such as the applied potential and the media diffusivities.
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4.2 The limit case P →∞: perfect contact
We now consider the limit case of P , that is when the contact between the vehicle and the target
tissue is perfect, and allows the continuity of the concentration in the interface between both media.
Differently from the previous subsection, the regularity of the concentration allows the use the
Poincare´ inequality. Let D, v and c be defined by:
D(x) = Di, v(x) = vi, c(x, t) = ci(x, t), x ∈ (xi−1, xi), i = 0, . . . , n.
with (3.6) replaced by:
J0 = J1, c0 = c1 at x = 0, (4.9)
Let (·, ·) be the usual inner product in L2(x−1, xn) and let ‖ · ‖ the corresponding norm. We
start by observing that we have
1
2
ξ′(t) = −(D∇c(t),∇c(t))− (vc(t),∇c(t)). (4.10)
Being
−(vc(t),∇c(t)) ≤ max
i=0,...,n
|vi|‖c(t)‖‖∇c(t)‖,
and taking into account the following Poincaire´ inequality ξ(t) ≤ L
2
2
‖∇c(t)‖2, we obtain
−(vc(t),∇c(t)) ≤ max
i=0,...,n
|vi| L√
2
‖∇c(t)‖2.
Inserting the last upper bound in (4.10) we deduce
ξ′(t) ≤
(
− 2 min
i=0,...,n
Di + max
i=0,...,n
|vi|
√
2L
)
‖∇c(t)‖2. (4.11)
If
max
i=0,...,n
|vi|
Di
L ≤
√
2. (4.12)
by applying the Poincare´ inequality in (4.11), we get
ξ(t) ≤ eβt‖c(0)‖2, (4.13)
where
β =
1
L2
(
− 2 min
i=0,...,n
Di + max
i=0,...,n
|vi|
√
2L
)
.
Under the condition (4.12) we get the mass upper bound:
M(t) ≤
√
Leβt‖c(0)‖. (4.14)
From equation (4.14), the decreasing of the upper bound for the drug mass M(t) is observed
provided that (4.12) holds.
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5 Nondimensional equations
Before solving the differential problem, all the variables, the parameters and the equations are now
normalized to get easily computable nondimensional quantities as follows:
x¯ =
x
L
t¯ =
Dmax
L2
t c¯i =
ci
C
δ =
l0
L
γi =
Di
Dmax
φ¯i =
Fzi
RT
φi Π =
PL
Dmax
(5.1)
where the subscript max denotes the maximum value across the n+ 1 layers2. By omitting the bar
for simplicity, the 1D nondimensional Nernst-Planck equations (3.1)–(3.2) become:
∂ci
∂t
= γi
∂2ci
∂x2
+ γi
(
∂ci
∂x
∂φi
∂x
+ ci
∂2φi
∂x2
)
= γi
∂2ci
∂x2
+ γiai
∂ci
∂x
i = 0, 1, . . . , n (5.2)
(cfr. with (3.13)). The above eqns are supplemented by the following boundary/interface condi-
tions:
J0 = −γ0
(
∂c0
∂x
+ a0c0
)
= 0 at x = −δ (5.3)
J0 = −γ0
(
∂c0
∂x
+ a0c0
)
= −γ1
(
∂c1
∂x
+ ac1
)
= J1
J0 = −γ0
(
∂c0
∂x
+ a0c0
)
= Π(c0 − c1) at x = 0 (5.4)
Ji = −γi
(
∂ci
∂x
+ aci
)
= −γi+1
(
∂ci+1
∂x
+ aci+1
)
= Ji+1
ci = ci+1 i = 1, . . . , n− 1 at x = xi (5.5)
cn = 0 at x = 1 (5.6)
and initial conditions:
c0(x, 0) = 1 ci(x, 0) = 0 i = 1, 2, . . . , n (5.7)
2The nondimensional quantity
Fφ
RT
=
uφ
D
=
u∇φL
D
=
[velocity] · [length]
[diffusivity]
measures the relative strength of
electrical driven convective to diffusive forces and corresponds to the Pe´clet number in fluid dynamics problems.
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6 Numerical solution
Although a semi-analytic treatment is possible in multi-layered diffusion problems [24], we pro-
ceed to solve the nondimensional system of equations (5.2)–(5.6) numerically. Let us subdivide
the interval (−δ, 0) into N0 + 1 equispaced grid nodes xj0 = (j −N0)h0, j = 0, 1, . . . , N0, and
the i−th interval [xi, xi+1] with Ni + 1 equispaced points xji = j hi, j = 0, 1, . . . , Ni. Here,
h0, h1, h2 . . . , hn represent the spacing in the vehicle (layer 0) and skin (layers i = 1, 2 . . . , n),
respectively3. In each layer, we approximate the diffusive terms by considering a standard finite-
difference of the second derivative and centered first derivative at internal nodes xj:
∂ci
∂x
∣∣∣∣
xj
' c
j+1
i − cj−1i
2hi
(6.1)
∂2ci
∂x2
∣∣∣∣
xj
' c
j−1
i − 2cji + cj+1i
h2i
j = 1, . . . , Ni − 1 i = 0, 1, . . . , n
At the boundary points x = −δ and x = 1 and at interfaces xi, the equations (5.2) hold, but
the approximations (6.1) include the boundary conditions (5.3)–(5.6) and the interface conditions
(5.5).
Treatment of the interface x = 0
At the interface x = 0, we potentially have a discontinuity in concentration and two possibly
different values, say c˜N0 and c˜
0
1 (the tilde accent indicates these special points) , each for each
interface side, need to be determined (fig. 4).
No derivative can be computed across the interface x = 0, due to a possible discontinuity and
approximations (6.1) no longer apply. An alternative procedure is needed in eqn (6.1) to get c˜N0 for
j = N0 − 1 and c˜01 for j = 1. Their values are related through the interface conditions (5.4):
− γ0
(
∂c˜N0
∂x
+ a0c˜
N
0
)
= −γ1
(
∂c˜01
∂x
+ ac˜01
)
− γ0
(
∂c˜N0
∂x
+ a0c˜
N
0
)
= Π(c˜N0 − c˜01) (6.2)
Following the approach described by Hickson et al. [25] , we take a Taylor series expansion for
3In the following, the subscript i refers to the layer, the superscript j denotes the approximated value of the
concentrations at xji .
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cN−20 , c
N−1
0 , c
1
1, c
2
1, and arrive at:
cN−10 ≈ c˜N0 − h0
∂c˜N0
∂x
+
h20
2
∂2c˜N0
∂x2
cN−20 ≈ c˜N0 − 2h0
∂c˜N0
∂x
+ 2h20
∂2c˜N0
∂x2
c11 ≈ c˜01 + h1
∂c˜01
∂x
+
h21
2
∂2c˜01
∂x2
c21 ≈ c˜01 + 2h1
∂c˜01
∂x
+ 2h21
∂2c˜01
∂x2
(6.3)
The two equations (6.2) and the four equations (6.3) form an algebraic system of six equations
that allow to express c˜N0 , c˜
0
1 and their first and second derivatives as a linear combination of the
neighboring values. Using symbolic calculus we obtain:
c˜N0 =
[γ0γ1(3− 2ah1) + 2Πγ0h1](cN−20 − 4cN−10 ) + 2γ1h0Π(c21 − 4c11)
Q
(6.4)
c˜01 =
[γ0γ1(3 + 2a0h0) + 2Πγ1h0](c
2
1 − 4c11) + 2γ0h1Π(cN−20 − 4cN−10 )
Q
(6.5)
where Q = 2γ1h0Π(2ah1 − 3) + γ0(2a0h0 + 3)(2aγ1h1 − 3γ1 − 2h1Π).
After spatial discretization, the system of PDEs reduces to a system of nonlinear ordinary differ-
ential equations (ODEs) of the form:
dY
dt
= A(Y ) (6.6)
where Y = (c00, . . . ., c
N−1
0 , c
1
1, . . . , c
N1
1 , . . . ., c
0
n, . . . .c
Nn
n )
T and A(Y ) contains the coupled N0 +
N1 + · · · + Nn discretized equations (5.2). The system (6.6) is solved by the routine ode15s of
Matlab based on a Runge-Kutta type method with backward differentiation formulas, and an
adaptive time step. The interface drug concentrations c˜N0 , c˜
0
1 are computed a posteriori through
equations (6.4)–(6.5).
7 Results and discussion
A common difficulty in simulating physiological processes, in particular TDD, is the identification
of reliable estimates of the model parameters. Experiments of TDD are impossible or prohibitively
expensive in vivo and the only available source are lacking and incomplete data from literature.
The drug delivery problem depends on a large number of constants, each of them varies in a finite
range, with a variety of combinations and limiting cases. Furthermore, these parameters can be
influenced by body delivering site, patient age and individual variability. They cannot be chosen
independently from each other and there is a compatibility condition among them.
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Here, the skin is assumed to be composed of three main layers, say the stratum corneum, the
viable epidermis, and the dermis with respective model parameters given in table 1. In the absence
of direct measurements, indirect data are inferred from previous studies in literature [4, 7, 26].
Diffusivities critically depend on the kind and size of the transported molecules and are affected
of a high degree of uncertainty. The vehicle-skin permeability parameter is estimated as P =
10−5cm/s.
Table 1: The parameters used in the simulations for the vehicle and the three skin layers.
— vehicle (0) stratum corneum (1) viable epidermis (2) dermis (3)
li = xi − xi−1(cm) 0.01 1.75 · 10−3 3.5 · 10−3 0.11
Di(cm
2/s) 10−4 10−10 10−7 10−7
σi(S/cm) 1.5 · 10−2 10−7 10−4 10−4
The coefficients of potential φi in eqn (3.13) have the following expressions:
a0 = −∆Ψσ1σ2σ3
G
b0 =
l0Ψ1σ1σ2σ3 + l1Ψ0σ0σ3(σ2 − σ1) + l2Ψ0σ0σ1(σ3 − σ2) + l3Ψ0σ0σ1σ2
G
a1 = −∆Ψσ0σ2σ3
G
b1 =
l0Ψ1σ1σ2σ3 + l1Ψ0σ0σ3(σ2 − σ1) + l2Ψ0σ0σ1(σ3 − σ2) + l3Ψ0σ0σ1σ2
G
= b0
a2 = −∆Ψσ0σ1σ3
G
b2 =
l0Ψ1σ1σ2σ3 + l1Ψ1σ0σ3(σ2 − σ1) + l2Ψ0σ0σ1(σ3 − σ2) + l3Ψ0σ0σ1σ2
G
a3 = −∆Ψσ0σ1σ2
G
b3 =
l0Ψ1σ1σ2σ3 + l1Ψ1σ0σ3(σ2 − σ1) + l2Ψ1σ0σ1(σ3 − σ2) + l3Ψ0σ0σ1σ2
G
(7.1)
where G = l0σ1σ2σ3 + l1σ0σ3(σ2 − σ1) + l2σ0σ1(σ3 − σ2) + l3σ0σ1σ2 and ∆Ψ = Ψ0 −Ψ1. Note
that only the electric potential gradients, ai, appear in the Nernst-Planck equation and the ratio of
the slopes satisfies:
ai
ai+1
=
σi+1
σi
.
Instead than reproducing the clinical protocols where iontophoresis consists in repeated ses-
sions of 10-20 mins, the numerical simulations aim at bringing to extreme values both the potential
(up to ∆Ψ = 10V ) and the duration of application (30 mins): a current is activated during this
period of time and then switched off. In fig. 5 the concentration profiles are shown before (contin-
uous lines) and after (dashed lines) the current application. The iontophoretic effect is to enhance
the stratum corneum permeation but, only for higher ∆Ψ, appears to be significant in deeper lay-
ers. No relevant effect is present after suspension. It is desirable the drug level is maintained over a
certain amount to exerts its therapeutic effect without exceeding a given threshold to not be toxic.
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In fig. 6 the different distribution of drug mass in all layers is depicted: mass is decreasing
in the vehicle, whereas in the other layers is first increasing, reaches a peak, and asymptotically
decreasing, as in other similar drug delivery systems [18, 24]. Due to the sink condition at the right
end, part of mass is lost via the systemic circulation. By considering this effect, a drug mass con-
servation holds and the progressive emptying of the vehicle corresponds to the drug replenishment
of the other layers – in a cascade sequence – at a rate depending of the electric field (fig. 6). Again,
an augmented transdermal permeation is reported with higher values of the potential: this is more
effective during current administration, but prolongs at later times (12h − 72h). The transport of
a species across skin will be determined by the strength and the duration of the electric field, the
concentration and the mobility of all ions in the skin. The desired delivery rate is obtained with a
proper choice of the physico-chemical-electrical parameters.
These outcomes provide valuable indications to assess whether drug reaches a deeper layer,
and to optimize the dose capacity in the vehicle. Therefore, it is possible to identify the conditions
that guarantee a more prolonged and uniform release or a localized peaked distribution.
8 Conclusions
Nowadays iontophoretic systems are commonly used in transdermal applications. These systems
use an electric field to enhance the release from a drug reservoir and to direct the therapeutic action
at the target tissue with a given rate and at desired level. Iontophoresis provides a mechanism to
control the transport of hydrophilic and charged agents across the skin, especially for high molec-
ular weight substances such as peptides or proteins which are usually ionized and hardly penetrate
the stratum corneum by conventional passive diffusion. Notwithstanding, the effective utilization
of electric field-assisted transport for drug delivery across biological membranes requires a deeper
understanding of the mechanisms and theories behind the process.
In this paper a multi-layer model is developed to clarify the role of the applied potential, the
conductivity of the skin, the drug diffusion and the systemic absorption. The stability of the math-
ematical problem is discussed within two different scenarios: imperfect and perfect contact be-
tween the reservoir and the target tissue. To illustrate the drug dynamics in the composite medium
- vehicle and skin layers coupled - during and after the electric administration, an accurate finite-
difference method is proposed. The modelling approach allows the simulation in several experi-
mental setting, including extreme conditions which are not possible in clinical environment. Nu-
merical experiments show to what extent the applied current, along the duration of application,
accelerates the depletion of the reservoir and increases the drug absorption in the deep skin. The
present TDD model constitutes a simple and useful tool in exploring new delivering strategies that
guarantee the optimal and localized release for an extended period of time.
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Figure 1: An anatomic representation of the skin, composed by three main layers: epidermis (ap-
proximately 100µm thick), dermis (between 1 and 3mm thick, highly vascularized) and a subcuta-
neous tissue. The epidermis is divided into sub-layers where the stratum corneum (approximately
15µm thick) is the outermost layer and is the major barrier to the drug migration, being composed
of densely packed cells, with a typical brick and mortar structure. Each skin layer, due to its
histological composition, has a different influence in the drug transport mechanism.
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Figure 2: A schematic section representing the present multi-layered model. A vehicle is applied
over the skin surface with an imperfect contact at the vehicle-skin interface (figure not to scale).
Figure 3: A diagram sketching a n-layered tissue (`1, `2, ..., `n) faced with the vehicle `0. The
1D model is defined along the line normal to the skin surface and extends with a sequence of n
contiguous layers from the vehicle interface x0 = 0 up to the skin bound xn = L, where capillaries
sweep the drug away to the systemic circulation (sink). In iontophoresis, a difference of potential
is applied to facilitate drug penetration from the vehicle across the tissue’s layers (figure not to
scale).
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Figure 4: Schematic illustration of grid nodes in the first two layers and the interface points (in red
and green). They are computed a posteriori as a linear combination of the neighbouring grid points
(eqns. (6.4)–(6.5)). At the other interfaces a single concentration values occur.
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Figure 6: Distribution of mass in all layers (including the vehicle (layer 0) and the sink) at five
times, for three differences of potential. The heights of the rectangles indicate the percentage of
mass retained in each layer. A higher current accelerates depletion of the vehicle and enhances
drug delivery in stratum corneum and in the deeper skin’s layers. At later times most of drug
results absorbed at the systemic level (current switched off after 30min).
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